ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 Million
July 30, 2021I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced that its Board of Directors has authorized a new stock repurchase program. With the Board's authorization ...
Pharma Sources Insight January 2025
